Abstract
Antiepileptic drugs (AEDs) have traditionally been associated with osteoporosis. However, recent studies have only shown a very limited increase in the risk of fractures with the use of some but not all AEDs. Patients with epilepsy have an increased risk of fractures, but this increase is mainly linked to fractures sustained during seizures. Patients with epilepsy may also have a decreased bone mineral density but this decrease is far too small to explain the increase in fracture risk. The decrease in bone mineral density is seen mainly in children with complicating diseases and developmental disorders that lead to vitamin D deficiency. Much of the increase in fracture risk may be due to the underlying disorder and the severity of seizures rather than to the drugs used to treat epilepsy. The prevention of seizures seems to be of greater importance than any potential detrimental effects of the AEDs on the skeleton, provided that vitamin D status is kept at an optimal level. From a fracture point of view most AEDs seem to be relatively safe.
Keywords: Epilepsy, Bone Turnover, Bone Mineral, Fracture Risk, Antiepileptic drugs, osteoporosis, vitamin D deficiency
Current Drug Safety
Title: Changes in Bone Turnover, Bone Mineral and Fracture Risk Induced by Drugs Used to Treat Epilepsy
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Epilepsy, Bone Turnover, Bone Mineral, Fracture Risk, Antiepileptic drugs, osteoporosis, vitamin D deficiency
Abstract: Antiepileptic drugs (AEDs) have traditionally been associated with osteoporosis. However, recent studies have only shown a very limited increase in the risk of fractures with the use of some but not all AEDs. Patients with epilepsy have an increased risk of fractures, but this increase is mainly linked to fractures sustained during seizures. Patients with epilepsy may also have a decreased bone mineral density but this decrease is far too small to explain the increase in fracture risk. The decrease in bone mineral density is seen mainly in children with complicating diseases and developmental disorders that lead to vitamin D deficiency. Much of the increase in fracture risk may be due to the underlying disorder and the severity of seizures rather than to the drugs used to treat epilepsy. The prevention of seizures seems to be of greater importance than any potential detrimental effects of the AEDs on the skeleton, provided that vitamin D status is kept at an optimal level. From a fracture point of view most AEDs seem to be relatively safe.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Changes in Bone Turnover, Bone Mineral and Fracture Risk Induced by Drugs Used to Treat Epilepsy, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699405
DOI https://dx.doi.org/10.2174/157488608785699405 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued) PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Longitudinal Functional MRI of Motor and Cognitive Recovery Following Stroke: A Review
Current Medical Imaging The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Localised Delivery of Therapeutic Agents to CNS Malignancies: Old and New Approaches
Current Pharmaceutical Biotechnology Sodium Channel Blocking Activity and In-vivo Testing of New Phenylimidazole Derivatives
Letters in Drug Design & Discovery Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy Structure Activity Relationships of Novel Antiepileptic Drugs
Current Medicinal Chemistry The Quantitative Structure-Activity Relationships between GABAA Receptor and Ligands based on Binding Interface Characteristic
Current Computer-Aided Drug Design Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Research Progress of the UPR Mechanism and its Effect on Improving Foreign Protein Expression
Protein & Peptide Letters Mitogenomics: Recognizing the Significance of Mitochondrial Genomic Variation for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry
Current Medicinal Chemistry Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Neurocognitive Functioning and Cannabis Use in Schizophrenia
Current Pharmaceutical Design EPO and EPO-Receptor System as Potential Actionable Mechanism for the Protection of Brain and Heart in Refractory Epilepsy and SUDEP
Current Pharmaceutical Design